Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NASAM: Neoadjuvant and Adjuvant Encorafenib/Binimetinib for In-transit Melanoma
NCT05767879Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2022
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of encorafenib, binimetinib in melanoma, sponsored by Leiden University Medical Center. Started Jan 2022; status: recruiting.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05767879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05767879.